BI 1181181

Drug Profile

BI 1181181

Alternative Names: BI-1181181; VTP-37948

Latest Information Update: 11 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim; Vitae Pharmaceuticals
  • Developer Boehringer Ingelheim
  • Class Nootropics; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 07 Apr 2015 Discontinued - Phase-I for Alzheimer's disease (In volunteers) in Belgium (PO)
  • 01 Apr 2015 Discontinued - Phase-I for Alzheimer's disease (In the elderly, In volunteers, In adults) in Germany (PO)
  • 01 Apr 2015 Boehringer Ingelheim terminates a phase I trial for Alzheimer's disease (In volunteers, In adults, In the elderly) in Germany (NCT02254161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top